SANUWAVE Health, Inc. announced that it has received $1.8 million in funding
June 17, 2024
Share
SANUWAVE Health, Inc announced it has entered into a Securities Purchase Agreement and has issued convertible Promissory Notes in aggregate principal amount of $1,800,000, first warrants to purchase an additional 32,500,000 shares of common stock of the Company with an exercise price of $0.067 per share and warrants to purchase an additional 32,500,000 shares of common stock of the Company with an exercise price of $0.04 per share for aggregate proceeds of $1,800,000 on June 18, 2024
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.